Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Actinic keratoses in sufficient numbers (\>10) to warrant PDT therapy in the clinic~* Able to understand and willing to sign a written informed consent document~* Female subjects must not become pregnant during the study:~  * The effects of 5-aminolevulinic acid (LevulanTM) on the human fetus are unknown. For this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. Should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately.~Exclusion Criteria:~* Pregnant or nursing.~* At risk for hypercalcemia (renal disease, sarcoidosis, etc.)~* Using topical retinoids, since these can exacerbate the post-PDT erythema reaction.~* Using any topical treatment on their AKs; must stop at least one month prior.~* Currently undergoing treatment for other cancers with medical or radiation therapy.~* Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.~* Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.~* Currently participating in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 + Photodynamic therapy (PDT) (Type: EXPERIMENTAL): Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).